View Author
Griffin, J.R.
( J.R. Griffin)
patient tiotropium exacerbation salmeterol ipratropium disease model england trial severity ib ory ite result disease severity resource use probability estimate health delphi panel treatment table cost-effectiveness outcome boehringer ingelheim ltd analysis budget impact utility resource budget impact analysis number saving study uk reference prices rim r copd patients r gani distribution value maintenance panel journal intervention state delphi thorax www.thepcrj.org reproduction 2008. hospital comparison pcrs-uk .14 admission copyright threshold month model inputs hospitalisation boehringer non-severe base-case copd cost-utility cycle respir limitation tiotropium vs ipratropium reference budget impact ingelheim difference willingness-to-pay thresholds pfizer uk ltd tiotropium patients exacerbation rates care trust scotland uncertainty netherland function reduction
2 Most Recent Publications
|
Economic analyses comparing tiotropium with ipratropium or salmeterol in UK patients with COPD
(Article)
Gani, R. Griffin, J.R. Kelly, S. Mölken, M.R.V. van |
2010-03-01
|
|
Identification and characterization of the human type II collagen gene (COL2A1).
(Article)
Cheah, K.S.E. Stoker, N.G. Griffin, J.R. Grosveld, F.G. Solomon, E. |
1985-01-01
|
